|
gptkbp:instanceOf
|
glycoprotein hormone
|
|
gptkbp:abbreviation
|
gptkb:EPO
|
|
gptkbp:administeredBy
|
injection
|
|
gptkbp:approvedDrugName
|
gptkb:darbepoetin_alfa
gptkb:epoetin_alfa
|
|
gptkbp:ATCCode
|
B03XA01
|
|
gptkbp:bannedIn
|
gptkb:World_Anti-Doping_Agency
|
|
gptkbp:binds
|
erythropoietin receptor
|
|
gptkbp:biosimilar
|
gptkb:epoetin_beta
gptkb:epoetin_zeta
|
|
gptkbp:CASNumber
|
11096-26-7
|
|
gptkbp:category
|
hormone
cytokine
hematopoietic growth factor
|
|
gptkbp:discoveredBy
|
gptkb:Allan_J._Erslev
|
|
gptkbp:discoveredIn
|
1953
|
|
gptkbp:foundIn
|
mammals
|
|
gptkbp:gene
|
gptkb:EPO_gene
|
|
gptkbp:halfLife
|
19-25 hours (SC)
4-13 hours (IV)
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
erythropoietin
|
|
gptkbp:marketedAs
|
gptkb:Janssen
gptkb:Pfizer
gptkb:Sanofi
gptkb:Sandoz
gptkb:Amgen
gptkb:Biocon
gptkb:Novartis
gptkb:Roche
gptkb:Hospira
gptkb:Cipla
Teva
|
|
gptkbp:medicalUse
|
chronic kidney disease
chemotherapy-induced anemia
|
|
gptkbp:molecularWeight
|
~34 kDa
|
|
gptkbp:producedBy
|
gptkb:kidney
liver
|
|
gptkbp:promotion
|
erythropoiesis
|
|
gptkbp:recipient
|
erythropoietin receptor
|
|
gptkbp:regulates
|
gptkb:hypoxia
red blood cell production
|
|
gptkbp:sideEffect
|
hypertension
thrombosis
|
|
gptkbp:structureType
|
gptkb:protein
|
|
gptkbp:UNII
|
QGJ0B9WMN1
|
|
gptkbp:usedFor
|
treatment of anemia
performance enhancement (doping)
|
|
gptkbp:usedIn
|
blood doping
|
|
gptkbp:bfsParent
|
gptkb:The_Synthesis_of_Haemoglobin
gptkb:kidney
|
|
gptkbp:bfsLayer
|
5
|